Most welcome to come work with us on our next big thing, a phase 2b study starting next year. Position filled.
Ilya Pharma Receives Approval from Swedish Regulators to Initiate Phase II Clinical Study of ILP100 Gene Therapy to Treat Difficult Wounds Patients with Diabetes
Pfizer veteran Sylvia McBrinn joins Board while Oskar Lund becomes CFO as Ilya Pharma strengthens senior management - top news shared by FirstWord Pharma
Ilya Pharma will present recent clinical data and planned studies for ILP100 Topical and Oral at Pharmabiotics 28-29 April 2021
Bio€quity hosts Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs. Ilya Pharma will share milestones and data from the clinical developments and the emerging pipeline.
Ilya Pharma awarded European patent covering engineered Lactobacillus reuteri strains for use in cutaneous wound therapy
Patent covers treatment of cutaneous human and animal wounds using transformed lactic acid bacteria
Ilya Pharma approved for funding by the European Innovation Council Equity Fund for high-impact innovation
Bloomberg reports: EU will become shareholder in startups for the first time.
Ilya Pharma announces positive results from Phase I trial of lead candidate ILP100 and rapid move to Phase II
Success also de-risks the use of ILP-drug candidates in other medical indications, including the company’s inflammatory bowel disease program.